Spero Therapeutics licenses antibody from Innovent in $1.1B deal

July 14, 2026 6:00 AM

Spero Therapeutics, Inc. (Nasdaq: SPRO) and Innovent Biologics, Inc. (01801.HK) announced an exclusive license agreement for SP001, also known as ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found